In contrast, for patients with high Ki-67 or Her2/neu positive breast cancer, CMF regimen was remarkably inferior to anthracycline/taxane-based regimens, but there was no significant difference in the therapeutic efficacy between anthracycline-based and taxane-based regimens regardless of breast cancer subtypes. The gene discussed is MKI67; the disease is breast carcinoma.